Talawar Therapeutics

Talawar Therapeutics is a biotechnology company focused on developing potentially best-in-class bispecific antibodies for immunology and inflammatory diseases. The company is building therapies that combine two clinically validated but complementary disease drivers into a single biologic, with the goal of improving efficacy beyond current monotherapy standards. Its lead program, TALA-125, is an anti-Interleukin-13 x anti-Interleukin-18 bispecific antibody being developed for atopic dermatitis, with clinical entry expected in the first quarter of 2027. Talawar was formed to develop and commercialize assets discovered by Khanda Therapeutics and, as of June 29, 2026, announced a definitive business combination with JATT II Acquisition Corp. that is expected to take the company public on Nasdaq under the ticker TLWR.